% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • censored53 censored53 Aug 23, 2013 9:32 AM Flag

    AEGR Doesn't Add Up


    with a manufactured Market Cap of 2,560 million, trailing twelve month losses of 73 million on revenue of 7.72 million (sales not profit). All for a drug (not cure) that effects one in a million diagnosed with a hereditary high cholesterol disorder, that less than one in a thousand of those diagnosed will be able to afford based upon the 300K annual price tag.

    United States 316,668,567 (July 2013 est.)
    European Union 503,890,016 (July 2013 est.)
    World 7,095,217,980 (July 2013 est.)

    one in a million afflicted means potential of 317 in USA, 504 in EU, or 7,095 prescriptions worldwide. How many of those do you think can afford ANNUAL 300K prescription?

    GDP per Capita
    United States $50,700 (2012 est.)
    European Union $35,100 (2012 est.)
    World $12,700 (2012 est.)

    per IRS statistics, applying affordability, the income cutoff for the top 1% of people who filed income tax returns in 2009 was 344K (1.38 million people), being generous that means approximately 1 in 200 in the USA could if they chose afford the prescription....Worldwide I'd have to assume fewer than 1 in 1000 of thos diagnosed will be able to afford prescription.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.21+0.02(+0.91%)Oct 21 4:00 PMEDT